{"created":"2023-05-15T11:22:36.784896+00:00","id":1230,"links":{},"metadata":{"_buckets":{"deposit":"c0107408-1552-47b5-b860-c5ac99aaefd0"},"_deposit":{"created_by":1,"id":"1230","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"1230"},"status":"published"},"_oai":{"id":"oai:showa.repo.nii.ac.jp:00001230","sets":["1:55:154"]},"author_link":["6469","6468"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2011-03"},"bibliographicIssueNumber":"8","bibliographicPageEnd":"67","bibliographicPageStart":"61","bibliographic_titles":[{"bibliographic_title":"昭和大学保健医療学雑誌"}]}]},"item_10002_description_6":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"メロキシカム(MEL)を投与した膝変形性関節症(OA)患者から関節液を採取し、細胞外マトリックス分解酵素(MMP)含有量の変動を観察するとともに、膝OA関節で認められる組織学的変化の発現検索に重要であると考えられている関節コラーゲン破壊産物、いわゆる関節マーカーの検出を試みた。膝OA患者12例を対象とした。関節液のMMP-2ならびにMMP-9は有意に減少したが、関節液のTIMP-1、TIMP-2含有量は薬剤投与前後で有意差は認めなかった。関節液中のCOMP、C2C、CTX-II含有量は、薬剤投与によりこれら関節軟骨破壊物質の著明な減少が観察された。MELの経口投与を受けた膝OA患者では罹患関節内においてMMP産生が抑制、さらにはコラーゲンの分解が阻止されることにより関節軟骨の破壊が妨げられ、これら一連の反応によって膝OA病態の進展が調節されている可能性が示唆された。","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"昭和大学保健医療学部"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1349-029X"}]},"item_10002_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"村松, 邦彦"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"浅野, 和仁"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-07-26"}],"displaytype":"detail","filename":"NR8_61.pdf","filesize":[{"value":"3.4 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"NR8_61.pdf","url":"https://showa.repo.nii.ac.jp/record/1230/files/NR8_61.pdf"},"version_id":"6a2d7a8e-bab0-4868-993d-ee905e78d670"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper"}]},"item_title":"COX-2阻害薬、メロキシカムの関節軟骨分解酵素産生抑制作用　変形性膝関節症患者を対象にした効果の解析","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"COX-2阻害薬、メロキシカムの関節軟骨分解酵素産生抑制作用　変形性膝関節症患者を対象にした効果の解析"}]},"item_type_id":"10002","owner":"1","path":["154"],"pubdate":{"attribute_name":"公開日","attribute_value":"2015-11-04"},"publish_date":"2015-11-04","publish_status":"0","recid":"1230","relation_version_is_last":true,"title":["COX-2阻害薬、メロキシカムの関節軟骨分解酵素産生抑制作用　変形性膝関節症患者を対象にした効果の解析"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T12:50:47.699995+00:00"}